Buparlisib (BKM120, NVP-BKM120)

目录号:S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献38篇:

客户使用该产品的6个实验数据:

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M121eGN6fG:2b4jpZ{BCe3OjeR?= NXntfpk3PzJiaB?= M2HheGROW09? NHrE[3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGW6cILld5NqdmdiUFmzT4FteGijIFW1OFVMKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFAyPThizszN NEfjWmwzPDlyMEK2Oi=>
DU145 M4fyPWN6fG:2b4jpZ{BCe3OjeR?= Mmf5O|IhcA>? MofiSG1UVw>? NGTiNVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2= NF;Pe|czPDlyMEK2Oi=>
A2780 NUjPd|I4S3m2b4TvfIlkKEG|c3H5 MnLiO|IhcA>? M1[zOWROW09? MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP NFfzbWszPDlyMEK2Oi=>
U87MG NFnXZ2FEgXSxdH;4bYMhSXO|YYm= NF;yRZc4OiCq M3HjfmROW09? M3HkfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= MYqyOFkxODJ4Nh?=
A2780 MnTYSpVv[3Srb36gRZN{[Xl? M2fCSFEhcA>? NIDaVYpFVVOR NXrMVplrUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= MXqyOFkxODJ4Nh?=
DU145 NG\NWYRHfW6ldHnvckBCe3OjeR?= NFPFZVAyKGh? MWTEUXNQ NXjTeWszUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2= M2XXTFI1QTByMk[2
A2780 MmLBSpVv[3Srb36gRZN{[Xl? MXyxJIg> Ml[zSG1UVw>? NXn6cm9LUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJGEzPzhyIHPlcIx{KHerdHigSWM2OCCxZjCwMlA4PCEQvF2= NV7nfldEOjR7MECyOlY>
MCF7 M1TwTGZ2dmO2aX;uJGF{e2G7 MUWxJIg> Mn24SG1UVw>? MnvLTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO Ml7SNlQ6ODB{Nk[=
U87MG NVnS[XhTTnWwY4Tpc44hSXO|YYm= NVLJWHN6OSCq MYfEUXNQ NWjwSoZNUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= Mn\xNlQ6ODB{Nk[=
A2780 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XhV|czKGh? M1f0UGROW09? MkjMSWM2OD1yLkWyJO69VQ>? NFu1NpAzPDlyMEK2Oi=>
SKMES-1 NYq5U5RqS3m2b4TvfIlkKEG|c3H5 MXuxJO69VQ>? NFfFe404OiCq NXz3WVV5UW6mdXPld{Bk\WyuIHTlZZRp NV\ROXh6OjZyMUOzNVg>
H596 NFH0OHlHfW6ldHnvckBCe3OjeR?= NIX4cnQyKM7:TR?= Mnj5TY1x[Wm{czDj[YxtKG2rZ4LheIlwdg>? MWqyOlAyOzNzOB?=
HCC2450 NFnDTGhHfW6ldHnvckBCe3OjeR?= M1PFe|Eh|ryP MlnLTY1x[Wm{czDj[YxtKGmwdnHzbY9v M{PFeFI3ODF|M{G4
A549 M{XIO2Z2dmO2aX;uJGF{e2G7 MkjZOVAxKG6P MnfOOFghcA>? M4OzeWROW09? M{CxcGlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w NHPmO3YzPTl|N{K5PS=>
A549 M17sbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P5[|Eh|ryP M{fVXVczKGh? MnzxSG1UVw>? NEO2SlFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3rmV|I2QTN5Mkm5
H522 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETGbFEyKM7:TR?= MlfHO|IhcA>? MUTEUXNQ MkPOTY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mo[5NlU6Ozd{OUm=
LNCaP MlW0SpVv[3Srb36gRZN{[Xl? MkD4NUDPxE1? NVLEXm1{W3WycILld5NmeyCyLVHLWEBt\X[nbIO= NVuyd3pVOjV|NkC3PVk>
LNCaP95 NU\IfG5QTnWwY4Tpc44hSXO|YYm= NHfoVncyKM7:TR?= NW[0T5diW3WycILld5NmeyCyLVHLWEBt\X[nbIO= NWDNd4dbOjV|NkC3PVk>
HCT-15 MlXyRZBwfG:|aYOgRZN{[Xl? NXGzV2dwOTBizszN NELVUYo1QCCq MXzEUXNQ NG\uUFdKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MmfINlUyPTJ{NEW=
HCT-116 MkjwRZBwfG:|aYOgRZN{[Xl? MYmxNEDPxE1? MlPyOFghcA>? NYnSV3UyTE2VTx?= MVHJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NHTi[pAzPTF3MkK0OS=>
NCI-H460 MnnSRZBwfG:|aYOgRZN{[Xl? NFG5SnYyOCEQvF2= MnHxOFghcA>? MX;EUXNQ MULJcoR2[2W|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MYiyOVE2OjJ2NR?=
SKOV-3 M33M[GFxd3Sxc3nzJGF{e2G7 M3z5WlExKM7:TR?= M1;jcVQ5KGh? NXnhS2FNTE2VTx?= NHn5V5hKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MlnoNlUyPTJ{NEW=
BSY-1 NG\CfZBCeG:2b4Ppd{BCe3OjeR?= NXL3S5dWOTBizszN NIHNU4U1QCCq NFL1NG1FVVOR NFH1[WdKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NEXhOm4zPTF3MkK0OS=>
MKN-1 NFjNXHRCeG:2b4Ppd{BCe3OjeR?= NY[yc5hkOTBizszN Mn;BOFghcA>? NX:wcW1vTE2VTx?= MYHJcoR2[2W|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v MknLNlUyPTJ{NEW=
NCI-H522 NIX1doNCeG:2b4Ppd{BCe3OjeR?= M1fSSFExKM7:TR?= M1\oRVQ5KGh? NFrGdGtFVVOR Mof0TY5lfWOnczDhdI9xfG:|aYO= MoTYNlUyPTJ{NEW=
OVCAR-3 M4DzemFxd3Sxc3nzJGF{e2G7 MmjxNVAh|ryP MlL3OFghcA>? MX;EUXNQ MVrJcoR2[2W|IHHwc5B1d3Orcx?= M36xcFI2OTV{MkS1
HBC-5 MknHRZBwfG:|aYOgRZN{[Xl? NF;tWVMyOCEQvF2= NV;CPHlZPDhiaB?= NYjPV|hCTE2VTx?= MWLJcoR2[2W|IHHwc5B1d3Orcx?= MoDMNlUyPTJ{NEW=
RXF-631L NFPIVJVCeG:2b4Ppd{BCe3OjeR?= NYrqPZBEOTBizszN NHO1emo1QCCq NVS4VVZPTE2VTx?= M2nUTmlv\HWlZYOgZZBweHSxc3nz NV;UTpFJOjVzNUKyOFU>
MKN-45 M2rKbGFxd3Sxc3nzJGF{e2G7 M{TGUVExKM7:TR?= NUO4N|B1PDhiaB?= M4XFZ2ROW09? MX7JcoR2[2W|IHHwc5B1d3Orcx?= NILJU3ozPTF3MkK0OS=>
BON-1 NX\ZW4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNOVAxKG6P M2fhTFExKGR? MUPEUXNQ M2DJNGlvcGmkaYTzJINmdGxiZ4Lve5Rp NXTk[3g1OjVyMk[yPVI>
BON-1 NHS1UotHfW6ldHnvckBCe3OjeR?= NEDQfZM2ODBibl2= MmD4OEBp Mk\iSG1UVw>? Ml3aTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MXWyOVAzPjJ7Mh?=
QGP-1 MVrGeY5kfGmxbjDBd5NigQ>? MYG1NFAhdk1? M3mxcVQhcA>? M{HvXWROW09? MnLDTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MoLFNlUxOjZ{OUK=
Huh7 MnLkSpVv[3Srb36gRZN{[Xl? M1TxVVEh|ryP Ml3PNUBp M{XhU2ROW09? M3rJR2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgV4VzPDd2 Mn3wNlUxODR2MEO=
BNL M{LBZ2Z2dmO2aX;uJGF{e2G7 Mo\KNUDPxE1? NGfvemoyKGh? MVvEUXNQ M33zO2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? M{L1bVI2ODB2NECz
MDA-MB-175 NFfIXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImyZ|YyKM7:TR?= M1y2O|Uh\A>? NHTycoxFVVOR NXPWZYNZUUN3MEyxJO69VQ>? NF:yNY8zPDh5OUe5Oi=>
MDA-MB-134 M1z4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLMNUDPxE1? Mni2OUBl Mnu4SG1UVw>? MlnFTWM2ODxzIN88US=> NFfGNYozPDh5OUe5Oi=>
HCC1500 M2SwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqPXYyKM7:TR?= MkWzOUBl MkLTSG1UVw>? M2f3ZmlEPTB:MTFOwG0> MUmyOFg4QTd7Nh?=
EFM-19 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTE[pN6OSEQvF2= NF:0[m02KGR? MnTSSG1UVw>? NU\t[Wo4UUN3MEyxJO69VQ>? MW[yOFg4QTd7Nh?=
ZR-75-30 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\McGcyKM7:TR?= NIfmUIQ2KGR? NEPzbpRFVVOR MmHUTWM2ODxzIN88US=> M33TWFI1QDd7N{m2
MDA-MB-361 NGHDXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXiNUDPxE1? M{nKdlUh\A>? NWfM[ZBNTE2VTx?= NVvveHVUUUN3MEyxJO69VQ>? NWfNWmVKOjR6N{m3PVY>
T-47D M3e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LJU|Eh|ryP Ml3HOUBl NV[xcW1qTE2VTx?= NIfYTolKSzVyPEGg{txO MV6yOFg4QTd7Nh?=
SK-BR-3 NU\COYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjhdW1bOSEQvF2= NEfJTmU2KGR? MkXrSG1UVw>? M4fHSWlEPTB:MTFOwG0> MWmyOFg4QTd7Nh?=
UACC-732 NF\wW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH6WHc4OSEQvF2= NYPmeWpNPSCm MYTEUXNQ MYTJR|UxRDFizszN M1\qTFI1QDd7N{m2
BT-474 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13oelEh|ryP NV:wfmk{PSCm MXfEUXNQ M{H5RWlEPTB:MTFOwG0> M2S4TFI1QDd7N{m2
HCC202 NUDaZZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;FZZUyKM7:TR?= MYW1JIQ> NIjzN3pFVVOR NWP3T|UyUUN3MEyxJO69VQ>? NEjrO3AzPDh5OUe5Oi=>
MCF7 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrHNUDPxE1? NGTINm42KGR? MUPEUXNQ MmTPTWM2ODxzIN88US=> MoewNlQ5Pzl5OU[=
MDA-MB-415 NFXPdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrOfocyKM7:TR?= M1rSfFUh\A>? NWDHV2pyTE2VTx?= MoDWTWM2ODxzIN88US=> NHrxZYkzPDh5OUe5Oi=>
MDA-MB-453 M2fh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0[lEh|ryP MUm1JIQ> NXnPdJB[TE2VTx?= MmrSTWM2ODxzIN88US=> Mkn0NlQ5Pzl5OU[=
ZR-75-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLoWHkyKM7:TR?= NV6xWnNLPSCm M2rnWWROW09? MlTvTWM2ODxzIN88US=> MnLHNlQ5Pzl5OU[=
HCC38 M3L2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjfYUyKM7:TR?= NWLOUphkPSCm M{jycWROW09? NIDISYhKSzVyPEGg{txO NH7iWIUzPDh5OUe5Oi=>
HCC1419 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPDbG9jOSEQvF2= Mni0OUBl MlPOSG1UVw>? NV7me2xUUUN3MEyxJO69VQ>? NXLaT3lJOjR6N{m3PVY>
UACC-812 M3;3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXhTZcyKM7:TR?= Mnf4OUBl NWHPZ4tjTE2VTx?= NIOwPYFKSzVyPEGg{txO M2H6bVI1QDd7N{m2
HCC1187 NGq4NWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fuTVEh|ryP MUK1JIQ> NVj0OYxxTE2VTx?= NELLV4JKSzVyPEGg{txO MnnNNlQ5Pzl5OU[=
KPL-1 M124UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13lXlEh|ryP MVG1JIQ> NWjIWY5lTE2VTx?= M4\3bGlEPTB:MTFOwG0> NWqyfYRpOjR6N{m3PVY>
SUM-225 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjrNUDPxE1? NWLSdY9TPSCm M4j0fWROW09? MX3JR|UxRDFizszN NV6yfYpuOjR6N{m3PVY>
EFM-192A NF7wV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvVNUDPxE1? NXTSN5VyPSCm MWLEUXNQ MkD2TWM2ODxzIN88US=> MYWyOFg4QTd7Nh?=
JIMT-1 NUnU[2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexJO69VQ>? MUW1JIQ> NGXoOWFFVVOR NWPmcoxOUUN3MEyxJO69VQ>? M1e1O|I1QDd7N{m2
HCC1143 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnseGwyKM7:TR?= NWTLZphTPSCm MVvEUXNQ M{[0N2lEPTB:MTFOwG0> Ml74NlQ5Pzl5OU[=
HCC2218 NVSxW3ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHnNUDPxE1? NUXPWHdCPSCm M{K3e2ROW09? MljWTWM2ODxzIN88US=> M1fXPVI1QDd7N{m2
MDA-MB-468 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nUWVEh|ryP MX[1JIQ> MUnEUXNQ M3fqUGlEPTB:MTFOwG0> MX[yOFg4QTd7Nh?=
BT-20 M1;JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfVeG8yKM7:TR?= MYK1JIQ> Mn:xSG1UVw>? MYrJR|UxRDFizszN MYqyOFg4QTd7Nh?=
MDA-MB-435 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX0NUDPxE1? NIL1fIY2KGR? NE\aS2NFVVOR NV\vclZvUUN3MEyxJO69VQ>? MYGyOFg4QTd7Nh?=
BT-549 NYrMVWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjzNUDPxE1? NYTIbIJRPSCm MXTEUXNQ MofmTWM2ODxzIN88US=> NIX2ZoozPDh5OUe5Oi=>
HCC1806 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxJO69VQ>? M{ft[VUh\A>? MmjqSG1UVw>? MVLJR|UxRDFizszN M2XSR|I1QDd7N{m2
HCC1937 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxJO69VQ>? NULYUIpmPSCm NH:3[nVFVVOR MWLJR|UxRDFizszN NXnVZZE5OjR6N{m3PVY>
Hs578T Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW0NUDPxE1? NYjyR4lsPSCm MnXVSG1UVw>? MlXHTWM2ODxzIN88US=> MojCNlQ5Pzl5OU[=
LN18 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVVlIxKM7:TR?= M4HPO|czKGh? M4LGOWROW09? M3jBZWlEPTB:NTFOwG0> M2nJbFI1PzRzMEe0
LN229 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmyN4p[OjBizszN MmH5O|IhcA>? MWPEUXNQ NGHPeIVKSzVyPEWg{txO MkPsNlQ4PDFyN{S=
LNZ308 NF\zd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nhfFIxKM7:TR?= Mnf1O|IhcA>? M1zpVGROW09? MVXJR|UxRDVizszN MoDaNlQ4PDFyN{S=
T98G NGLmcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[yNEDPxE1? MoPIO|IhcA>? MnL0SG1UVw>? M4DRU2lEPTB:NTFOwG0> NELHOVAzPDd2MUC3OC=>
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jSSVIxKM7:TR?= M3PYO|czKGh? NUXFNG5sTE2VTx?= M3jRZ2lEPTB:NTFOwG0> Mon1NlQ4PDFyN{S=
LN18 MWrGeY5kfGmxbjDBd5NigQ>? MmW5OUDPxE1? NG\XSGczPCCq MUfEUXNQ MoPWTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MWmyOFc1OTB5NB?=
LNZ308 NHXVXYdHfW6ldHnvckBCe3OjeR?= MlLZOUDPxE1? NVHsNHhPOjRiaB?= MnLHSG1UVw>? MmnGTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? M2PoV|I1PzRzMEe0
Saos-2 MkPFSpVv[3Srb36gRZN{[Xl? MYm1NEDPxE1? MYG0PEBp MkXGTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MnnmNlQ4Ojd4NkC=
MG-63 M{nqXmZ2dmO2aX;uJGF{e2G7 NFzKRZM2OCEQvF2= MUG0PEBp NEG1c21KdmirYnn0d{Bk\WyuIHnueoF{cW:w Ml\5NlQ4Ojd4NkC=
SJSA-1 M{fne2Z2dmO2aX;uJGF{e2G7 NHvJVpE2OCEQvF2= NWrHRVdKPDhiaB?= NW\ybopCUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MmLlNlQ4Ojd4NkC=
Saos-2 MVfGeY5kfGmxbjDBd5NigQ>? MWS1NEDPxE1? NHLuVog1QCCq MnWzTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> MnHPNlQ4Ojd4NkC=
MG-63 NWjDc5Z[TnWwY4Tpc44hSXO|YYm= MYK1NEDPxE1? M{TnRVQ5KGh? NWPme5piUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MXOyOFczPzZ4MB?=
SJSA-1 M17ONmZ2dmO2aX;uJGF{e2G7 MXK1NEDPxE1? MWC0PEBp MknBTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> NGmzR5IzPDd{N{[2NC=>
Saos-2 NUD0XYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq1NEDPxE1? MYC0PEBp NFP6S4NKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NF\kSpYzPDd{N{[2NC=>
MG-63 NHjhOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnixOVAh|ryP MWG0PEBp M3iycGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NWrSNXB2OjR5Mke2OlA>
SJSA-1 NVewcFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm1NEDPxE1? NXnXOnNKPDhiaB?= M1P1OmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NFnpS|YzPDd{N{[2NC=>
FaDu M4ntXGZ2dmO2aX;uJGF{e2G7 NUnVWoJxPSEQvF2= M13XbVI1KGh? MYTEUXNQ MV\S[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NVPs[nlLOjR4M{GxOFc>
EMT6 MonSSpVv[3Srb36gRZN{[Xl? NXfCVm9UPSEQvF2= MWOyOEBp NEjBVGtFVVOR Ml;NVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M1rtZlI1PjNzMUS3
HCT116 NFLsd4NHfW6ldHnvckBCe3OjeR?= Mlu1OUDPxE1? NV7TcHdTOjRiaB?= MonPSG1UVw>? M3XoOXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u M{TtSVI1PjNzMUS3
U87 M1jiZmZ2dmO2aX;uJGF{e2G7 Ml\wOUDPxE1? MVKyOEBp M1\ieGROW09? NVTsZ|k1WmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> M33sRlI1PjNzMUS3
GBM MUjBdI9xfG:|aYOgRZN{[Xl? MWqy{txO NHnBSGs1QGh? NFPEOG5FVVOR M4nOZYlv\HWlZXSgbIlocGW{IHzleoVteyCxZjDhdI9xfG:|aYOsJIFv\CCmZXPy[YF{\WRiY3XscEB3cWGkaXzpeJk> M3OxXVI1PTByNEmy
BON NX:0R|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXuWFkyNTYQvF2= NGDIV4I4Omh? Ml7Z[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> M1vod|I1PDR|NUKz
BON NXXUTINvSXCxcITvd4l{KEG|c3H5 Mn\aNU02|ryP NVLYblFtOjSq Mm\UbY5kemWjc3XzJIFxd3C2b4Ppdy=> M3Pp[FI1PDR|NUKz
H1975 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2UlQ3OC5|LUmuOu69VQ>? MXe3Nog> MV3EUXNQ MULJR|UxRTFwM{i1{txO MnzuNlQ{Ozd6NE[=
H1975 NVXW[2w{SXCxcITvd4l{KEG|c3H5 NXH0c5k3Os7:TR?= NWfFV4tVOjSq MUnEUXNQ Mn;UbY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk> MVKyOFM{Pzh2Nh?=
T-ALL MlPURZBweHSxc3nzJGF{e2G7 MYfi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV? Mn:5NlQhd3JiNEjo MYDEUXNQ MmTZZYZn\WO2czD0bIUhWEl|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO= MX:yOFMyODd|Nh?=
BCR-ABL NIPrZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzzNE4zPS1zMN88US=> M4Tu[lRl M3XFSpNq\26rZnnjZY51dHliaX7obYJqfCClZXzsJJBzd2yrZnXyZZRqd25? Ml7pNlQzPDR4MUK=
LC-1/SQSF MWrGeY5kfGmxbjDBd5NigQ>? NG\HXWU{|ryP MWWyOIg> Ml3nSG1UVw>? MmX6[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs MXSyN|k5ODB7Mx?=
Primary CLL cells M3zlT2Fxd3C2b4Ppd{BCe3OjeR?= NXK0PG9vOS1zMN88US=> NEXvXpQ1QGh? MVjpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz NEHCZ2MzOzh3MEiwOy=>
Primary CLL cells M17obWtqdmG|ZTDBd5NigQ>? M1vwOlLPxE1? M2\uc|MxdWmw M{ewNoRm[3KnYYPl[EBRUTONIHHjeIl3cXS7 NHv5PYczOzh3MEiwOy=>
Primary CLL cells Mn\nR5l1d3SxeHnjJGF{e2G7 M1L4bFLPxE1? Mnr2NlRp NEfaXVRqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5 MnjVNlM5PTB6MEe=
human NSCLC cell lines NUPLXXdmSXCxcITvd4l{KEG|c3H5 MWOwMlEzPS12zszN NHm2VnMzPGh? NXjKb3BpTE2VTx?= MV3JR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= MmPaNlM2PjJ2N{K=
human HCC cell lines MXjD[YxtKH[rYXLpcIl1gSCjc4PhfS=> M3XpWVAvODB3LUJOwG0> NEfKXpI1QGh? NYXIXYZsUUN3ME2x{txO MkHSNlM1QDl7OUm=
Huh7 NET6VYpMcW6jc3WgRZN{[Xl? NVrOTlRSOc7:TR?= NELGPHc1QGh? M4rod5Nq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> M3PSZ|I{PDh7OUm5
SK-HEP1 NInCfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv0bpgyNTJyzszN M1nC[|czcA>? M2O0RmROW09? M13YZmlEPTExvKyx{txO NVPCfpBHOjN2N{mxN|Y>
786-0 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXvNU0zOM7:TR?= M4[0TlczcA>? MnLaSG1UVw>? Mn62TWM2OO,:nEJOwG0> NEPLXJczOzR5OUGzOi=>
JVM2 NYrOdZNiS3m2b4TvfIlkcXS7IHHzd4F6 MX:wMlIuOjEQvF2= MVu3Nog> MkDDSG1UVw>? MVXJR|UxRTBwOd88US=> MVeyN|I{QDZ|OR?=
EHEB Ml;CR5l1d3SxeHnjbZR6KGG|c3H5 NEDtR4kxNjJvMkFOwG0> M{\sd|czcA>? M{TI[2ROW09? M{HPWGlEPTB;MD63{txO NFn0cYUzOzJ|OE[zPS=>
MEC2 M1uwbmN6fG:2b4jpZ4l1gSCjc4PhfS=> NXLxZmFTOC5{LUKw{txO MnHTO|Jp MWTEUXNQ NG\mbFdKSzVyPUCuO:69VQ>? M4rzU|I{OjN6NkO5
primary B-CLL lymphocytes MoLqRZBweHSxc3nzJGF{e2G7 MlTkTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? NEe5RYIzPGh? NFzKeVlFVVOR NUG2dXFOUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>? MlzTNlMzOzh4M{m=
primary B-CLL lymphocytes M2jye2tqdmG|ZTDBd5NigQ>? M4fHVWlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? MoO0NlRp MWrpcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= NEexNFIzOzJ|OE[zPS=>
human NSCLC MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFflb5gxNjVvMt88US=> MXi3Nog> MlvpTWM2OD1zzszN M3WyR|IzPzhzM{mz
human NSCLC Mk\3T4lv[XOnIFHzd4F6 M1nufFHPxE1? NY\Pd2V1OjSq NHKxOJFqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 NXPicnlrOjJ5OEGzPVM>
Y1 cell line M3j6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPoNE4y|ryPL{JOwG0> M17BWlI1cA>? MkDDSG1UVw>? MVjpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>? MX6yNlY6OjlyNB?=
PIK3CA-mutant MCF7 NIjEWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjXd5FIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= MojHO|Jp NFrpWHpIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= M1PNflIzPjV|OU[3
PIK3CA-mutant MCF7 NEfubVNMcW6jc3WgRZN{[Xl? NXziN45wUUN3ME2xNVTDuTOwTR?= NWny[WtlPzKq MVLJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| MnniNlI3PTN7Nke=
MCF7-myr-Akt M13hZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jiN2dKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P NHLLS2c4Omh? MY\HTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? MXyyNlY2Ozl4Nx?=
colon cancer cell lines NXHEO|V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LYcFAuOTEQvF2= M2PQeFczcA>? MkG5SG1UVw>? NVTkR|dVUUN3ME2x{txO MojqNlI2PDN6NUe=
gastric cancer cell lines NX\3PJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMVEx|ryP NHfrR204Omh? MoTHSG1UVw>? MVnJR|UxRTJvNd88US=> NVq4S2VtOjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 NWrmb|k4SXCxcITvd4l{KEG|c3H5 NGPr[msz|ryP M3y5UFQ5cA>? NITle5B{cGmodDDpckBIOiCyaHHz[S=> MnH1NlI2PDN6NUe=
HT-29 and HCT-116 NVe3cplsS2G|cHHz[UBie3OjeR?= M3\pU|XPxE1? MkLuNlRp M2\4WYlv\HWlZYOgZ4F{eGG|ZTDhZ5Rqfmm2eR?= Ml65NlI2PDN6NUe=
MM cell lines MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;2NVDPxE1? M2fkXVI1cA>? NWXhNYhtTE2VTx?= MVPJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> NUn4eXV3OjJ{MEe0PFU>
ARP-1 NUnScVlVSXCxcITvd4l{KEG|c3H5 M4\LcFEx|ryP NYXp[5M4OjSq NFjW[3FFVVOR Mne2bY5lfWOnczDNUUBk\WyuIHHwc5B1d3OrczD0bJJwfWeqIHPhd5Bie2ViYXP0bZZifGmxbh?= MYCyNlIxPzR6NR?=
SNU-601 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PDNVczcA>? NGT6ZWNFVVOR MkHXTWM2OD1yLkixOuKyOC5yNkROwG0> MXGyNlE2QThzNB?=
SNU-1 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX23Nog> M4\lTGROW09? NWDzNXQxUUN3ME2xMlA5OsLzMD6wNljPxE1? Mo\YNlIyPTl6MUS=
SNU-668 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW1UVI2PzKq M2HiSWROW09? NVTMdGJNUUN3ME2xMlU4QcLzMD6wO|TPxE1? M{HJWVIzOTV7OEG0
AGS NIXMO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuzZVRCPzKq NUX0Vo9JTE2VTx?= NF\kflRKSzVyPUGuO|E1yrFyLkGxO:69VQ>? MUGyNlE2QThzNB?=
SNU-216 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzsR|E4Omh? MUHEUXNQ NWW3OYtVUUN3ME2yMlY6OsLzMD6wPFLPxE1? MXeyNlE2QThzNB?=
SNU-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW3Nog> NWTJ[ZdwTE2VTx?= NXHWXnBvUUN3ME2xMlM2OcLzMD6wPVHPxE1? NHPRdnIzOjF3OUixOC=>
SNU-638 NGf2S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXnO|Jp NFfqd5VFVVOR M{nmTWlEPTB;Mj6yPFLDuTBwMEWz{txO NGDpVYszOjF3OUixOC=>
SNU-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPUblg4Omh? MV3EUXNQ M2r5fWlEPTB;MT61O|PDuTBwMECx{txO NHXDZW0zOjF3OUixOC=>
SNU-484 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\pbGk4Omh? NE[zcmJFVVOR M{TPTWlEPTB;MT63NljDuTBwMES1{txO NXf2Vo1KOjJzNUm4NVQ>
SNU-620 M3PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7uUnU2PzKq NUDWN2NFTE2VTx?= NVvJOHdCUUN3ME2yMlk{QcLzMD6wNFHPxE1? M3nyZlIzOTV7OEG0
SNU-719 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLO|Jp M1XjZWROW09? MXLJR|UxRTNwMEO3xtExNjB|Mt88US=> MnPFNlIyPTl6MUS=
glioma cell lines MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\KZWk4Omh? MXvJR|UxRTFvMt88US=> NX7G[2ltOjJyNkWwPFA>
U87 M3vzbWFxd3C2b4Ppd{BCe3OjeR?= MojtNu69VQ>? MX:3Nog> MmDYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= MXWyNlA3PTB6MB?=

... Click to View More Cell Line Experimental Data

体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID